Biomet Press Release
April 06 2006 - 12:47PM
Business Wire
Biomet, Inc. (NASDAQ:BMET) confirmed today that Morgan Stanley
& Co. Incorporated is assisting it in exploring strategic
alternatives focused on enhancing shareholder value. The Company
stated that no decisions have been made and there is no assurance
that this exploration will result in any specific action. Daniel P.
Hann, interim President and Chief Executive Officer, said, "We
believe that this review is a prudent exercise and is consistent
with management's commitment to our shareholders and Team Members."
The Company also stated that it does not expect to disclose
developments with respect to its exploration of alternatives unless
required. Biomet, Inc. and its subsidiaries design, manufacture and
market products used primarily by musculoskeletal medical
specialists in both surgical and non-surgical therapy. The
Company's product portfolio encompasses reconstructive products,
including orthopedic joint replacement devices, bone cements and
accessories, and dental reconstructive implants; fixation products,
including electrical bone growth stimulators, internal and external
orthopedic fixation devices, craniomaxillofacial implants and bone
substitute materials; spinal products, including spinal stimulation
devices, spinal hardware and orthobiologics; and other products,
such as arthroscopy products and softgoods and bracing products.
Headquartered in Warsaw, Indiana, Biomet and its subsidiaries
currently distribute products in more than 100 countries. For
further information contact Greg W. Sasso, Vice President,
Corporate Development and Communications at (574) 372-1528 or
Barbara Goslee, Manager, Corporate Communications at (574)
372-1514. This press release contains certain statements that are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, as amended. Although the Company believes
that the assumptions, on which the forward-looking statements
contained herein are based, are reasonable, any of those
assumptions could prove to be inaccurate given the inherent
uncertainties as to the occurrence or non-occurrence of future
events. There can be no assurance that the forward-looking
statements contained in this press release will prove to be
accurate. The inclusion of a forward-looking statement herein
should not be regarded as a representation by the Company that the
Company's objectives will be achieved. All of Biomet's financial
information may be obtained on our website at www.biomet.com or you
may contact us by e-mail at investor.relations@biometmail.com.
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biomet (NASDAQ:BMET)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biomet (MM) (NASDAQ): 0 recent articles
More Biomet, Inc. News Articles